Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

A new study reveals that semaglutide, a common diabetes medication, may effectively treat fatty liver disease, offering hope ...

Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with ...

A decision is expected in the fourth quarter of 2025.

Italy: A recent multicentre real-world study supports the long-term effectiveness of once-weekly semaglutide as a valuable ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

Semaglutide — known by brand names Ozempic and Wegovy — works in the brain to impact satiety. Over the past two years, the ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...